172 related articles for article (PubMed ID: 35610242)
1. Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma.
Birts CN; Savva C; Laversin SA; Lefas A; Krishnan J; Schapira A; Ashton-Key M; Crispin M; Johnson PWM; Blaydes JP; Copson E; Cutress RI; Beers SA
Sci Rep; 2022 May; 12(1):7802. PubMed ID: 35610242
[TBL] [Abstract][Full Text] [Related]
2. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer.
Maliniak ML; Cheriyan AM; Sherman ME; Liu Y; Gogineni K; Liu J; He J; Krishnamurti U; Miller-Kleinhenz J; Ashiqueali R; He J; Yacoub R; McCullough LE
Breast Cancer Res; 2020 Jun; 22(1):65. PubMed ID: 32552729
[TBL] [Abstract][Full Text] [Related]
3. Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients.
Zwager MC; Holt-Kedde I; Timmer-Bosscha H; de Bock GH; Werker PMN; Schröder CP; van der Vegt B; Arjaans M
Breast Cancer Res Treat; 2024 Feb; 204(1):27-37. PubMed ID: 38057686
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
6. Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.
Mullooly M; Yang HP; Falk RT; Nyante SJ; Cora R; Pfeiffer RM; Radisky DC; Visscher DW; Hartmann LC; Carter JM; Degnim AC; Stanczyk FZ; Figueroa JD; Garcia-Closas M; Lissowska J; Troester MA; Hewitt SM; Brinton LA; Sherman ME; Gierach GL
Breast Cancer Res; 2017 Jan; 19(1):8. PubMed ID: 28103902
[TBL] [Abstract][Full Text] [Related]
7. Macrophagic "Crown-like Structures" Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease.
Carter JM; Hoskin TL; Pena MA; Brahmbhatt R; Winham SJ; Frost MH; Stallings-Mann M; Radisky DC; Knutson KL; Visscher DW; Degnim AC
Cancer Prev Res (Phila); 2018 Feb; 11(2):113-119. PubMed ID: 29167285
[TBL] [Abstract][Full Text] [Related]
8. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
[TBL] [Abstract][Full Text] [Related]
9. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab.
Honkanen TJ; Moilanen T; Karihtala P; Tiainen S; Auvinen P; Väyrynen JP; Mäkinen M; Koivunen JP
Sci Rep; 2017 Dec; 7(1):18027. PubMed ID: 29269742
[TBL] [Abstract][Full Text] [Related]
11. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Kanomata N; Kurebayashi J; Moriya T
Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
15. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer.
Morris PG; Hudis CA; Giri D; Morrow M; Falcone DJ; Zhou XK; Du B; Brogi E; Crawford CB; Kopelovich L; Subbaramaiah K; Dannenberg AJ
Cancer Prev Res (Phila); 2011 Jul; 4(7):1021-9. PubMed ID: 21622727
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
Chumsri S; Li Z; Serie DJ; Mashadi-Hossein A; Colon-Otero G; Song N; Pogue-Geile KL; Gavin PG; Paik S; Moreno-Aspitia A; Perez EA; Thompson EA
J Clin Oncol; 2019 Dec; 37(35):3425-3435. PubMed ID: 31622131
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
